A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate the Safety, Tolerability and Immunogenicity of pPJV7630, a Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused by HSV-2

NCT00274300 Phase 1 COMPLETED

The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the ability of vaccine to cause particular immune responses in the body and evaluate the effect it has on herpes outbreaks

Details

Lead sponsor	PowderMed
Phase	Phase 1
Status	COMPLETED
Enrolment	36
Start date	2004-08
Completion	2005-07

Conditions

• HSV-2

Interventions

• pPJV7630 administered by PMED

Primary outcomes

• Adverse Events at all visits
• vaccine site evaluations
• laboratory parameters pre and post vaccination

Countries

United States